Within the ICC framework, bone marrow fibrosis did not lead to further differentiation in survival outcomes across the genetic subgroups of MDS with mutated TP53, and MDS/AML with MDS-related gene mutations (Supplementary Figs. 8 and 9). The gene discussed is TP53; the disease is intrahepatic cholangiocarcinoma.